The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AARD | N/A | N/A | N/A | -31% |
| S&P | +13.19% | +87.83% | +13.42% | +10% |
Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders. Aardvark Therapeutics was founded by Tien Lee in 2017.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.01M | 88.5% |
| Market Cap | $288.35M | 0.0% |
| Market Cap / Employee | $4.00M | 0.0% |
| Employees | 72 | 0.0% |
| Net Income | -$16.32M | -290.1% |
| EBITDA | -$17.69M | -253.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $39.29M | -52.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.12M | -78.7% |
| Short Term Debt | $0.43M | 32.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -44.96% | 0.0% |
| Return On Invested Capital | -63.72% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$18.52M | 0.0% |
| Operating Free Cash Flow | -$18.52M | 0.0% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Book | -2.98 | 1.95 | 2.11 | - | |
| Price to Tangible Book Value | -2.98 | 1.95 | 2.11 | - | |
| Enterprise Value to EBITDA | -1.18 | -9.61 | -9.22 | - | |
| Return on Equity | -110.4% | -48.1% | - | ||
| Total Debt | $0.78M | $0.73M | $0.65M | $0.55M | -37.21% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
